Qwadra, the digital division of Eqwal Group, has announced an exclusive licence agreement with BEGO Medical GmbH covering the use of patented 3D belt printing technology for the continuous manufacturing of foot orthotics, including custom insoles.
The agreement, announced in Eindhoven on 19 May 2026, gives Qwadra exclusive commercial exploitation rights for 3D belt printers used in this specific orthotic insole segment. For orthotic laboratories, podiatry providers and O&P clinics, the deal is significant because it places Qwadra and its PodoPrinter / Arkad platform in a stronger position within the rapidly developing market for automated, digital insole production.
The orthotic insole market is moving quickly from manual and semi-digital workflows toward integrated scan, design and print systems. For clinics and laboratories, this shift is not only about replacing traditional materials or fabrication methods. It is about changing the economics of production.
3D belt printing is particularly relevant because it supports continuous manufacturing. Instead of printing single parts on a fixed build plate, belt-based systems can allow serial production of insoles in a more automated workflow. This can be especially useful for laboratories producing multiple custom foot orthoses every day, where throughput, repeatability, material control and operator time are major commercial considerations.
By securing exclusive rights for this application, Qwadra is positioning itself as a reference player in 3D belt printing for foot orthotics. The agreement may also give the company greater confidence to invest in product development, technical support, training and international expansion.
Qwadra and PodoPrinter have already been active in 3D belt printing solutions for orthopedists, podiatrists and orthotic laboratories. The PodoPrinter platform is built around a dedicated digital workflow for custom and medical insoles, combining insole software, foaming filament and belt-based 3D printing.
The new BEGO Medical licence strengthens this positioning at a time when digital insole manufacturing is becoming more competitive. Across the global market, clinics and labs are evaluating different approaches, including CNC milling, FDM printing, SLS, MJF and hybrid semi-custom workflows. Belt printing offers a specific advantage for providers looking for continuous production, reduced manual handling and a more industrialised approach to foot orthotic manufacturing.
For larger orthotic laboratories, this could support higher-volume production. For progressive podiatry and O&P clinics, it may also create opportunities to bring more fabrication in-house, reducing dependency on external labs and improving turnaround times.
For orthotic and prosthetic professionals, the announcement should be viewed as part of a broader change in the foot orthotics market. Digital manufacturing is no longer a niche technology. It is becoming part of mainstream clinical and commercial strategy.
The key implications include:
However, the technology does not replace clinical decision-making. A 3D printed insole still depends on appropriate assessment, prescription, design choices, material selection and patient review. For clinical providers, the opportunity is not simply to buy a printer. The opportunity is to connect digital production with better patient pathways.
BEGO Medical is best known in the dental industry, where it has long experience in CAD/CAM workflows, digital manufacturing and additive technologies. Its background includes laser melting, milling and resin-based 3D printing for customised dental prosthetics.
The agreement with Qwadra shows how technologies and intellectual property from one medical manufacturing sector can influence another. Dental laboratories have often moved faster than O&P in adopting industrialised digital workflows. The transfer of expertise and patented technology into orthotic insole production may accelerate similar changes in podiatry and orthotics.
Exclusive licensing can be a powerful strategic tool in a fast-growing technology segment. For Qwadra, the agreement gives clearer control over a defined area of belt printing for foot orthotics. For competitors, it may influence how they approach printer design, intellectual property, partnerships and market access.
For the wider orthotics sector, the announcement reinforces a larger trend: digital insole manufacturing is becoming more structured, more protected and more commercially mature. The market is moving beyond early experimentation and into platform competition, where companies will seek differentiation through patents, software ecosystems, materials, training, support and clinical validation.
For the Middle East, Africa and wider IMEA region, technologies such as 3D belt printing could be important if they are matched with the right service model.
Many countries in the region face shortages of trained orthotic technicians, long delivery timelines, inconsistent access to materials and limited local manufacturing capacity. Digital insole production may help some clinics and laboratories increase consistency and reduce dependence on imported semi-finished components or overseas fabrication.
However, affordability, training, maintenance, materials supply and after-sales support will be critical. A high-performance digital system only creates value if clinics can integrate it into daily practice, train staff properly and maintain quality control.
For IMEA providers, the most important lesson is not that every clinic needs 3D belt printing immediately. The lesson is that foot orthotics is becoming a technology-led market. Clinics and laboratories that ignore digital manufacturing risk falling behind competitors who can deliver faster, more consistent and more scalable orthotic services.
Qwadra’s exclusive licence from BEGO Medical is more than a corporate announcement. It is a sign of where custom orthotic manufacturing is heading: toward protected digital platforms, integrated workflows and more industrialised production models.
For O&P clinics, podiatrists and orthotic laboratories, the message is clear. Digital orthotics is no longer only about scanning or CAD design. It is increasingly about complete manufacturing ecosystems that combine software, materials, printer architecture, intellectual property and technical support.
The winners in this next stage of foot orthotics will not be those who simply adopt technology for its own sake. They will be the providers who combine digital production with clinical expertise, appropriate prescription and reliable patient outcomes.